Elizabeth R. Plimack

Oct 11, 2024 | urologytimes.com | Elizabeth R. Plimack

In this interview, Elizabeth R. Plimack, MD, MS, FASCO, discusses the recent European Urology paper, “Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial.” Plimack is deputy director of Fox Chase Cancer Center and professor of hematology and oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania.

Nov 16, 2023 | onclive.com | Robert J. Motzer |Elizabeth R. Plimack

Future Perspectives in the Treatment of Advanced RCCOncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.

Oct 27, 2023 | onclive.com | Robert J. Motzer |Elizabeth R. Plimack

Key Takeaways in the Treatment of Advanced RCC From KCRS 2023Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.

Oct 27, 2023 | onclive.com | Robert J. Motzer |Elizabeth R. Plimack

Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCCDrs Elizabeth Plimack and Robert Motzer discuss the long-term toxicities of combination lenvatinib/pembrolizumab in patients with advanced RCC, highlighting fatigue, GI discomfort, hand-foot syndrome, liver toxicity, thyroid toxicity, and proteinuria.

Oct 20, 2023 | onclive.com | Robert J. Motzer |Elizabeth R. Plimack

Dosing Considerations for Combination Lenvatinib and Pembrolizumab in Patients with Advanced RCCExperts detail their approaches to dosing combination lenvatinib and pembrolizumab for patients with advanced RCC, emphasizing individualized treatment for balanced efficacy and toxicity.